Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk ​concerns raised by the U.S. FDA, and explore strategic options ‌including a potential sale or merger.